Cargando…

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant

The newly emerged Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains more than 30 mutations on the spike protein, 15 of which are located within the receptor binding domain (RBD). Consequently, Omicron is able to extensively escape existing neutralizing antibodi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zang, Jinkai, Yin, Yannan, Xu, Shiqi, Qiao, Weihua, Liu, Qiuyue, Lavillette, Dimitri, Zhang, Chao, Wang, Haikun, Huang, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280631/ https://www.ncbi.nlm.nih.gov/pubmed/35844601 http://dx.doi.org/10.3389/fimmu.2022.908478

Ejemplares similares

Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines
por: Yang, Yong, et al.
Publicado: (2021)

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023)

Scanning the RBD-ACE2 molecular interactions in Omicron variant
por: Rath, Soumya Lipsa, et al.
Publicado: (2022)

mRNA vaccines expressing homo-prototype/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2
por: Han, Yuxuan, et al.
Publicado: (2022)

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
por: Zhang, Jing, et al.
Publicado: (2022)

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
por: Luo, Deyan, et al.
Publicado: (2022)

Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants
por: Jia, Liqiu, et al.
Publicado: (2022)

Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
por: Xu, Kun, et al.
Publicado: (2022)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants
por: Xie, Yudi, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2
por: Wang, Ruoke, et al.
Publicado: (2022)

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022)

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
por: Zhao, Xin, et al.
Publicado: (2022)

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
por: Hernández-Luis, Pablo, et al.
Publicado: (2022)

A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2
por: Yao, Hebang, et al.
Publicado: (2021)

Omicron variants of SARS-CoV-2 and long COVID
por: Yang, Chengliang, et al.
Publicado: (2022)

Post-Vaccination Neutralization Responses to Omicron Sub-Variants
por: Jacobsen, Henning, et al.
Publicado: (2022)

Neutralization, effector function and immune imprinting of Omicron variants
por: Addetia, Amin, et al.
Publicado: (2023)

Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
por: Zhang, Yuntao, et al.
Publicado: (2022)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Neohesperidin and spike RBD interaction in omicron and its sub-variants: In silico, structural and simulation studies
por: Singh, Jaikee Kumar, et al.
Publicado: (2023)

A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy
por: Meng, Lu, et al.
Publicado: (2023)

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
por: Zang, Jinkai, et al.
Publicado: (2021)

COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood
por: Govindaraj, Sakthivel, et al.
Publicado: (2023)

Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex
por: Ching, Wai-Yim, et al.
Publicado: (2022)

Neutralization susceptibility of Omicron lineages
por: Minton, Kirsty
Publicado: (2022)

Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose
por: Belik, Milja, et al.
Publicado: (2023)

Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants
por: da Costa, Clauber Henrique Souza, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
por: Rescigno, Maria, et al.
Publicado: (2023)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Neutralization and Stability of SARS-CoV-2 Omicron Variant
por: Zeng, Cong, et al.
Publicado: (2021)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency
por: Mariotti, Sabrina, et al.
Publicado: (2021)

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
por: Miyamoto, Sho, et al.
Publicado: (2022)

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
por: Gagne, Matthew, et al.
Publicado: (2022)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays
por: Passariello, Margherita, et al.
Publicado: (2023)

Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera
por: Katzmarzyk, Maeva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kb5cudn9l3iintijdb2786pgp0